Search results
Showing 211 to 225 of 628 results for prescribing
Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making
Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)
This quality standard covers recognition, early intervention and long-term management of bipolar disorder, psychosis and schizophrenia in children and young people (under 18). It also includes support for parents and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS102Show all sections
Sections for QS102
- Quality statements
- Quality statement 1: Assessment for a first episode of psychosis
- Quality statement 2: Family intervention
- Quality statement 3: Psychological intervention
- Quality statement 4: Support for carers
- Quality statement 5: Healthy lifestyle advice
- Quality statement 6: Monitoring for side effects of antipsychotic medication
- Quality statement 7 (developmental): Home treatment in crisis
Melatonin for treating sleep disorders in adults who are blind (ES38)
Summary of the evidence on melatonin for treating sleep disorders in adults who are blind
View a complete list of indicators currently being developed. Our indicators measure outcomes that reflect the quality of care or processes.
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.
Sickle cell disease: managing acute painful episodes in hospital (CG143)
This guideline covers managing acute painful sickle cell episodes in children, young people and adults who present at hospital, from presentation until when they are discharged. It aims to reduce variation in how acute episodes are managed in hospital, focusing on effective, prompt and safe pain relief.
This guideline covers assessing and managing food allergy in children and young people under 19. It aims to improve symptoms such as faltering growth and eczema by offering advice on how to identify food allergy and when to refer to secondary or specialist care.
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
Community pharmacies: promoting health and wellbeing (NG102)
This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448
In development Reference number: GID-TA11564 Expected publication date: 22 July 2026
including anticipating and managing adverse effects, and engaging patients in prescribing decisions? Any explanatory notes(if...
This guideline covers new buildings and communal outdoor areas. The aim is to ensure there are enough shady areas to protect people from overexposure to the sun.
The adoption and implementation team provides support to the system to enable the effective use of NICE guidance.